drugset / Trial / NCT02499003
GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma
Phase 2
Completed
70 enrolled
Johannes Gutenberg University Mainz
Roche Pharma AG · collabServier · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the overall response rate of Obinutuzumab (GA101) in combination with Pixantrone in patients with relapsed aggressive B-cell lymphoma. 70 patients with diffuse large B-cell lymphoma, follicular lymphoma grade IIIB or transformed indolent lymphoma will receive up to 6 cycles of the described combination regimen. Follow up visits are scheduled for up to 3 years.
Timeline
- Start
- 2015-08-14
- Primary completion
- 2019-01-02
- Completion
- 2022-01-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Obinutuzumab | Monoclonal antibody | 1000 mg | — |
| Subject | Pixantrone | Small molecule | 50 mg/m2 | — |